MicroRNA Overexpression and Knockdown in Rat Cardiomyocytes: Functional Implications

MicroRNAs (miRNAs) are critical regulators of gene expression in cardiomyocytes, modulating processes such as hypertrophy, apoptosis, and electrophysiological remodeling. The ability to manipulate miRNA levels through overexpression or knockdown in rat cardiomyocytes provides insights into cardiac development, disease mechanisms, and potential therapeutic targets. Achieving efficient transfection of miRNA mimics or inhibitors into primary rat cardiomyocytes is technically challenging due to their post-mitotic nature, sensitivity to cytotoxic agents, and limited proliferative capacity.

For overexpression studies, chemically synthesized miRNA mimics are delivered using lipid-based transfection reagents optimized for cardiomyocytes, with formulations such as Lipofectamine RNAiMAX demonstrating enhanced uptake and reduced toxicity. Transfection efficiency depends on parameters including cell density, reagent-to-RNA ratio, and incubation time, all of which must be optimized to balance maximal miRNA expression with cellular viability. For knockdown, chemically modified antisense oligonucleotides such as locked nucleic acids (LNAs) or antagomirs are used to specifically inhibit endogenous miRNAs. Delivery of these inhibitors often employs similar transfection reagents or nanoparticle systems to facilitate cellular uptake and avoid endosomal trapping.

Expression vectors containing cardiac-specific promoters, such as α-myosin heavy chain, have been utilized to drive miRNA overexpression with tissue specificity in vivo. Viral vectors like adeno-associated viruses (AAV9) also serve as efficient tools for long-term modulation of miRNAs in rat hearts, allowing for systemic or localized delivery. Functional consequences of miRNA modulation are assessed using assays that measure changes in gene targets via qPCR and Western blotting, alterations in cardiomyocyte size and morphology through immunocytochemistry, and electrophysiological parameters using patch-clamp recordings or multielectrode arrays.

In vivo, delivery of miRNA modulators through intracardiac injection or systemic administration in rat models of myocardial infarction or heart failure enables the study of miRNA roles in pathological remodeling and regeneration. Echocardiography and hemodynamic measurements complement molecular analyses to evaluate cardiac function changes. Off-target effects and immune responses are minimized through sequence design, chemical modifications, and delivery route optimization. Overall, precise manipulation of miRNA levels in rat cardiomyocytes provides a powerful approach to dissecting cardiac gene regulatory networks and developing RNA-based therapeutics for cardiovascular diseases.